bioRxivBioinformaticsPreprint
Explainable Artificial Intelligence for Cross-Dataset Generalizable Biomarker Discovery in Cardiovascular diseases (CVDs)
Ahtisham Fazeel Abbasi, Muhammad Sajjad, Sebastian Vollmer, Andreas Dengel, Muhammad Nabeel AsimiD
Abstract
CVDs are heterogeneous, multifactorial disorders that remain the leading cause of global mortality from infancy to old age. It requires an early identification and treatment of risk factors to accelerate disease prevention and morbidity improvement. Advancements in transcriptomics technologies gives large pool of heterogenous gene expression data. The technical heterogeneity of gene expression data reduces ability to compare multiple cross-platform datasets at once. To bridge gap, we systematically evaluate three data harmonization techniques: Shambhala-2, TDM, and UPC to align heterogeneous data into a shared expression space while preserving biological signals. Our pipeline integrates 25 independent datasets comprising 983 samples across 23 distinct CVDs phenotypes from both RNA-seq and microarray platforms. The framework benchmarks 35 Machine learning (ML) and Deep learning (DL) classifiers, including Transformers and ResNets, across three data modalities such as RNA-seq, microarray hybridization and RNA-seq + microarray and multiple tissue types. To ensure clinical trustworthiness, we apply multiple Explainable artificial intelligence (XAI) methods, such as SHapley additive exPlanations (SHAP) and Integrated gradientss (IGs), and assess their reliability using quantitative metrics like Area over the perturbation curve (AOPC), Sensitivity, and Infidelity. Results indicate that Shambhala-2 provides superior harmonization by maximizing the biological signal-to-platform ratio. Evaluation of XAI methods reveals that Shapley-based approaches offer the highest stability for identifying influential genomic features in high-dimensional data. Functional enrichment and pathway analyses further confirmed the involvement of identified biomarkers in key cardiovascular processes, including inflammation, immune regulation, oxidative stress, and vascular remodeling. Collectively, this study provides a scalable and interpretable road-map that integrates XAI with cross-dataset biomarker discovery, supporting the transition toward precision cardiology.
- organism: human
- assay: bulk RNA-seq
- research focus: benchmarking
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
- approach: machine learning (classical)
- approach: deep learning
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multimodal AI/ML for discovering novel biomarkers and predicting disease using multi-omics profiles of patients with cardiovascular diseases
William DeGroat, Habiba Abdelhalim, … Zeeshan Ahmed·Scientific ReportsPeer-reviewed·Nov 3, 2024
- Discovering biomarkers associated and predicting cardiovascular disease with high accuracy using a novel nexus of machine learning techniques for precision medicine
William DeGroat, Habiba Abdelhalim, … Zeeshan Ahmed·Scientific ReportsPeer-reviewed·Jan 2, 2024
- CardioWAS Pathway-Based RNA-Seq and Genome Integration Platform for CVD Omics-Wide Associations
Yuvraj Singh, Nikhil Sharma, … Alokkumar Jha·bioRxiv·Oct 6, 2025
- HeartBioPortal: an internet-of-omics for human cardiovascular disease data
Bohdan B. Khomtchouk, Kasra A. Vand, … Themistocles L. Assimes·Circulation: Genomic and Precision MedicinePeer-reviewed·Apr 1, 2019
- Artificial Intelligence Powered Biomarker Discovery: A Large-Scale Analysis of 236 Studies Across 19 Therapeutic Areas and 147 Diseases
Ahtisham Fazeel Abbasi, Shiza Naveed, … Andreas Dengel·bioRxiv·Aug 28, 2025
- Explainable AI Based Coronary Heart Disease Prediction: Enhancing Model Transparency in Clinical Decision Making
Avichandra Singh Ningthoujam, Shilpa Sharma, Avishek Nandi·bioRxiv·Mar 20, 2025